Inclusion Criteria:  Treatment with immune checkpoint inhibitors (atezolizumab (Tecentriq®), avelumab (Bavencio®), cemiplimab (Libtayo®), durvalumab (Imfinzi®), ipilimumab (Yervoy®), nivolumab (Opdivo®) and pembrolizumab (Keytruda®)) Willingness and ability to provide written informed consent Age 18 years or older  Exclusion Criteria: n/a (real-world)